Leflutrozole
Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men.[1] It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued.[1] As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism.[1]
Clinical data | |
---|---|
Other names | BGS-649; CGP-47645 |
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H10FN5 |
Molar mass | 303.300 g·mol−1 |
3D model (JSmol) | |
| |
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.